SCHEMBL1975657

SCHEMBL1975657

COc1ccc(C(Cl)(c2ccc(OC)cc2)c2ccc(OC)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.58
CA2 P00918 2/20 0.58
CA7 P43166 2/20 0.58
CA9 Q16790 2/20 0.58
CA12 O43570 1/20 0.58
CA14 Q9ULX7 1/20 0.58
TDP1 Q9NUW8 5/20 0.52
MAPK1 P28482 5/20 0.52
ALDH1A1 P00352 5/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
TSHR P16473 2/20 0.52
ACHE P22303 1/20 0.48
MAPT P10636 3/20 0.44
KDM4E B2RXH2 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
RECQL P46063 2/20 0.44
NPC1 O15118 1/20 0.44
GAA P10253 1/20 0.44
THRB P10828 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21880569 0.93 ESR2 (0.52) CA1CA2CA7CA9CA12
SCHEMBL121800 0.91 CA4 (0.54) CA1CA2CA7CA9CA12
SCHEMBL13940030 0.91 ACHE (0.65) CA1CA2CA7CA9CA12
SCHEMBL16698731 0.91 CA4 (0.54) CA1CA2CA7CA9CA12
SCHEMBL4157842 0.91 ACHE (0.65) CA1CA2CA7CA9CA12
SCHEMBL26862 0.91 CA4 (0.54) CA1CA2CA7CA9CA12
SCHEMBL13939384 0.89 APP (0.48) CA1CA2CA7CA9CA12
SCHEMBL21551879 0.89 CA4 (0.52) CA1CA2CA7CA9CA12
Ammonia Solution, Strong SCHEMBL17187816 0.89 CA4 (0.52) CA1CA2CA7CA9CA12
SCHEMBL13096614 0.89 NFE2L2 (0.53) CA1CA2CA7CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119504882-A Synthesis method of GalNAc derivative 北京炫景瑞医药科技有限公司 2025-02-25 CN claimed
CN-119019354-A Compound and preparation method and application thereof 北京炫景瑞医药科技有限公司 2024-11-26 CN claimed
EP-4217508-A1 APPARATUS, KITS AND METHODS FOR PREDICTING THE DEVELOPMENT OF SEPSIS THE SECRETARY OF STATE FOR DEFENCE (GB) 2023-08-02 EP claimed
WO-2022064163-A1 APPARATUS, KITS AND METHODS FOR PREDICTING THE DEVELOPMENT OF SEPSIS THE SECRETARY OF STATE FOR DEFENCE (GB) 2022-03-31 WO claimed
CN-114249786-A Preparation and application of nucleoside intermediate containing N, N-diacyl structure 上海彩迩文生化科技有限公司 2022-03-29 CN claimed
US-4800166-A TRITYL HALIDE OR CARVOXYLATE TO BIND WITH FREE AMINO GROUPS APPLIED PROTEIN TECHNOLOGIES, INC. (US) 1989-01-24 US claimed
US-20260125413-A1 UNIVERSAL SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE SYNTHESIS AM CHEMICALS LLC (US) 2026-05-07 US disclosed
WO-2025111589-A1 COMPOSITIONS AND METHODS FOR ENHANCING DRUG RESISTANCE IN CELLS MEDICI THERAPEUTICS, INC. (US) 2025-05-30 WO disclosed
WO-2024240101-A9 GALNAC COMPOUND, CONJUGATE, COMPOSITION, AND USE THEREOF 北京炫景瑞医药科技有限公司 2025-03-06 WO disclosed
CN-119504882-A Synthesis method of GalNAc derivative 北京炫景瑞医药科技有限公司 2025-02-25 CN disclosed
US-20250042931-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS Azura Ophthalmics Ltd. (IL) 2025-02-06 US disclosed
WO-2024240101-A1 GALNAC COMPOUND, CONJUGATE, COMPOSITION, AND USE THEREOF 北京炫景瑞医药科技有限公司 2024-11-28 WO disclosed
CN-119019354-A Compound and preparation method and application thereof 北京炫景瑞医药科技有限公司 2024-11-26 CN disclosed
US-4800166-A TRITYL HALIDE OR CARVOXYLATE TO BIND WITH FREE AMINO GROUPS APPLIED PROTEIN TECHNOLOGIES, INC. (US) 1989-01-24 US disclosed
EP-0135587-A4 DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS. MOLECULAR BIOSYSTEMS INC (US) 1986-04-02 EP disclosed
EP-0135587-A1 DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS. MOLECULAR BIOSYSTEMS INC (US) 1985-04-03 EP disclosed
WO-1984003285-A1 DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS MOLECULAR BIOSYSTEMS INC (US) 1984-08-30 WO disclosed
US-4203898-A ANTICARCINOGENIC ELI LILLY AND COMPANY (US) 1980-05-20 US disclosed
US-4082736-A NOVEL IMMUNOLOGICAL ADJUVANT COMPOUNDS AND METHODS OF PREPARATION THEREOF SYNTEX (U.S.A.) INC. (US) 1978-04-04 US disclosed
US-4082735-A NOVEL IMMUNOLOGICAL ADJUVANT COMPOUNDS AND METHODS OF PREPARATION THEREOF SYNTEX (U.S.A.) INC. (US) 1978-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250042931-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS MPO, MUC1, CRYAB CA1 609/4885CA2 1218/4885CA7 519/4885
US-20260125413-A1 UNIVERSAL SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE SYNTHESIS SSU72, NSUN2, POLR2H CA1 1306/4885CA2 1718/4885CA7 1397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.